Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.
Mesa RA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2021)
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.
Royston D. et al, (2021), Hematol Oncol Clin North Am, 35, 279 - 293
CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 96 - 96
Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 101 - 102
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Mapperley C. et al, (2021), J Exp Med, 218
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
Louka E. et al, (2021), Journal of Experimental Medicine, 218
Application of Single Cell Approaches to Study MPN biology
MEAD A., (2021), Hematology / Oncology Clinics of North America
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S. et al, (2021), Future oncology (London, England)
TARGET-Seq: A Protocol for High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.
Rodriguez-Meira A. et al, (2020), STAR protocols, 1, 100125 - 100125
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Gerds AT. et al, (2020), Blood Adv, 4, 5825 - 5835
A novel human fetal liver-derived model reveals that MLL-AF4 drives a distinct fetal gene expression program in infant ALL
Rice S. et al, (2020), bioRxiv
Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study
Harrison C. et al, (2020), BLOOD, 136
Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN
Brierley CK. et al, (2020), BLOOD, 136
Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia
Iskander D. et al, (2020), BLOOD, 136
Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia.
Moreira LM. et al, (2020), Nature, 587, 460 - 465
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.
Shah V. et al, (2020), Leukemia, 34, 3091 - 3096
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
Smith G. et al, (2020), Br J Haematol, 191, 171 - 193
Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms.
Greenfield G. et al, (2020), Cancers (Basel), 12